Dogwood Phase 2b for Chemotherapy Induced Neuropathy to Start

  Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biopharmaceutical company focused on advancing first-in class, non-opioid, Nav 1.7 inhibitor treatments for chronic and acute pain, announced today that dosing of the first patient in its Phase 2b clinical trial, referred to as HALT-CINP (Halneuron® Treatment of Chemotherapy Induced Neuropathic Pain), evaluating Halneuron® to treat neuropathic pain associated with prior chemotherapy treatment (“CINP”) is expected to occur in the first quarter of 2025.

https://www.globenewswire.com/news-release/2025/01/21/3012781/0/en/Dogwood-Therapeutics-Announces-Patient-Dosing-in-Phase-2b-Trial-Evaluating-Halneuron-in-Patients-with-Chemotherapy-Induced-Neuropathy-CINP-to-Commence-First-Quarter-of-2025.html